Heart Health Depends on Sticking With GLP‑1 Drugs

A recent study examined the records of over 333,000 veterans with type‑2 diabetes who were treated through the Veterans Health Administration. The focus was on patients taking GLP‑1 medications—such as semaglutide (Ozempic) and tirzepatide (Mounjaro)—and compared their outcomes to those on sulfonylureas.

Key Findings

• Patients on GLP‑1 drugs for about three years enjoyed an 18 % lower risk of heart attacks, strokes, or death.
• Once the medication was stopped, that benefit dissipated rapidly—within just a year and a half.

The authors coined this phenomenon “metabolic whiplash.” They highlight that while it takes years to build cardiovascular protection, only a few months are needed for the body to lose that advantage.

Context from Other Research

• The SELECT trial reported a similar 20 % reduction in major heart events with semaglutide for obesity, even when weight loss was not achieved. This suggests a direct cardiac effect of GLP‑1 drugs.

Real‑World Implications

• Adherence issues: Many patients discontinue GLP‑1 therapy within a year due to side effects (nausea, fatigue) or cost. About half stop because of insurance gaps after reaching a weight goal.
• Unanswered question: It remains unclear whether maintaining a lower dose or preserving weight loss can sustain heart benefits after stopping the drug.

Takeaway

Continuous use of GLP‑1 medicines appears essential for maintaining cardiovascular health in people with type‑2 diabetes. Insurers and patients must recognize that discontinuation can expose individuals to unnecessary risk.